Pfizer Expects Rebate Reform By HHS Will Extend Quickly To Private Market
CEO Ian Read offers view of what’s ahead in US drug pricing reform based on his recent meeting with President Trump at the White House.
You may also be interested in...
HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.
Albert Bourla will face opportunities and potential pitfalls.
US FDA can encourage and increase competition, but cannot force generic companies to enter markets deemed unprofitable, CDER director says.